BIOVIE INC. BIVI
or "our") is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative
disorders and advanced liver disease.
of NeurMedix, Inc. ("NeurMedix") a privately held clinical-stage pharmaceutical company and a related party in June 2021.
The acquired assets included NE3107 ("bezisterim"). Bezisterim, the approved generic name for NE3107 is an investigational,
Last close
1.24
2026-10-23
Market cap
$9.4M
2026-06-30 share count
52-week range
0.82 - 3.79
Valuation FY2026 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.05
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $14.0M | $9.3M | $23.1M | $33.3M | $17.3M | $2.5M | $1.2M | $1.0M | $370.9K | $466.4K |
| SG&A | $8.5M | $8.6M | $8.8M | $11.6M | $9.8M | $4.6M | $1.3M | $1.3M | $1.8M | $69.1K |
| Total operating expenses | $22.7M | $18.1M | $32.2M | $45.1M | $27.3M | $138.1M | $2.7M | $2.5M | $2.4M | $1.6M |
| Operating income | -$22.7M | -$18.1M | -$32.2M | -$45.1M | -$27.3M | -$138.1M | -$2.7M | -$2.5M | -$2.4M | -$1.6M |
| Interest expense | $17.9K | $332.7K | $2.9M | $4.3M | $2.2M | $559.5K | $4.8M | $273 | $41.0K | — |
| Net income | -$22.1M | -$17.5M | -$32.1M | -$50.3M | -$26.1M | -$130.2M | -$16.7M | -$2.4M | -$2.4M | -$1.3M |
| EPS, basic | -3.05 | -12.12 | -73.05 | -15.47 | -1.06 | -14.82 | -6.85 | -0.98 | — | — |
| EPS, diluted | -3.05 | -12.12 | -73.05 | -15.47 | -1.06 | -14.82 | -6.85 | -0.98 | -0.03 | -0.01 |
| Shares, diluted (wtd. avg.) | 7.2M | 1.5M | 451,853 | 3.2M | 24.7M | 12.4M | 4.9M | 2.5M | — | — |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.0M | $17.5M | $23.8M | $19.5M | $18.6M | $4.5M | $37.2K | — | — | — |
| Total current assets | $13.6M | $20.7M | $24.0M | $34.0M | $18.8M | $4.6M | $413.0K | $674.1K | $45.8K | $5.1K |
| Goodwill | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K | $345.7K |
| Other intangibles | — | $178.3K | $407.7K | $637.1K | $866.5K | $1.1M | $1.3M | $1.6M | $1.8M | $2.0M |
| Total assets | $14.3M | $21.6M | $25.2M | $35.1M | $20.1M | $6.0M | $2.1M | $2.6M | $2.2M | $2.4M |
| Accounts payable | $3.7M | $2.2M | $3.6M | $3.5M | $2.4M | $996.4K | $1.3M | $443.5K | $884.2K | $471.0K |
| Total current liabilities | $3.8M | $2.3M | $9.4M | $14.5M | $4.2M | $996.4K | $23.5M | $443.5K | $1.2M | $631.0K |
| Long-term debt | — | — | — | — | — | — | $62.5K | — | — | — |
| Total liabilities | $4.0M | $2.6M | $9.7M | $19.8M | $16.4M | $996.4K | $23.6M | $443.5K | $2.1M | $1.2M |
| Retained earnings | -$374.3M | -$352.1M | -$334.2M | -$301.2M | -$251.0M | -$224.9M | -$41.0M | -$7.3M | -$4.8M | -$2.3M |
| Total equity | $10.3M | $19.0M | $15.5M | $15.3M | $3.7M | $5.1M | -$21.5M | $2.1M | $111.2K | $1.2M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.0M | -$19.0M | -$27.9M | -$40.3M | -$19.0M | -$10.5M | -$1.6M | -$2.5M | -$621.3K | -$623.6K |
| Stock-based compensation | $2.3M | $1.2M | $2.8M | $4.2M | $5.8M | $3.0M | $24.8K | $64.9K | $238.2K | — |
| Investing cash flow | — | — | $14.5M | -$14.3M | — | — | — | — | — | — |
| Financing cash flow | $10.5M | $12.7M | $17.8M | $55.4M | $33.1M | $14.9M | $1.3M | $2.8M | $662.0K | $505.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001520138-26-000332.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
Recent filings and events
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |